Access cutting-edge endometrial cancer treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access endometrial cancer specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related endometrial cancer treatment provided free
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Sponsor: Acrivon Therapeutics
Check if you qualify for this endometrial cancer clinical trial in Phoenix, AZ
If you're searching for endometrial cancer treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced endometrial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.